Evidence map›Paper›PMID 36644946›Full record

ArticleClinical chemistry2023

High-Density Lipoprotein Lipidomics in Chronic Kidney Disease.

Benjamin Lidgard, Andrew N Hoofnagle, Leila R Zelnick, Ian H de Boer, Amanda M Fretts, Bryan R Kestenbaum, Rozenn N Lemaitre, Cassianne Robinson-Cohen, Nisha Bansal

Abstract read
In one paragraph

Article in Clinical chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Observational
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Benjamin LidgardDepartment of Medicine, University of Washington, Seattle, USA.ORCID 0000-0003-0484-4385
Andrew N HoofnagleDepartment of Medicine, University of Washington, Seattle, USA.ORCID 0000-0002-6449-0243
Leila R ZelnickDepartment of Medicine, University of Washington, Seattle, USA.
Ian H de BoerDepartment of Medicine, University of Washington, Seattle, USA.
Amanda M FrettsDepartment of Medicine, University of Washington, Seattle, USA.
Bryan R KestenbaumDepartment of Medicine, University of Washington, Seattle, USA.
Rozenn N LemaitreDepartment of Medicine, University of Washington, Seattle, USA.
Cassianne Robinson-CohenDepartment of Medicine, Vanderbilt University, Nashville, USA.ORCID 0000-0003-4783-7046
Nisha BansalDepartment of Medicine, University of Washington, Seattle, USA.

Funding

PILOT STUDY--CLINICAL NUTRITION RESEARCHP30DK035816 · NIDDK · UNIVERSITY OF WASHINGTON · PI Ellen A Schur · 1986 to 2026
$30.4M
RESEARCH TRAINING IN RENAL DISEASET32DK007467 · NIDDK · UNIVERSITY OF WASHINGTON · PI BANSAL, NISHA, KESTENBAUM, BRYAN R · 1986 to 2023
$5.1M
Impact of Clonal Hematopoiesis on the Progression of Kidney DiseaseR01DK132155 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI HARRIS, RAYMOND C., KESTENBAUM, BRYAN R · 2022 to 2025
$2.5M
Investigating causality between abnormalities of mineral metabolism and kidney, cardiovascular and bone diseaseR01DK122075 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI ROBINSON-COHEN, CASSIANNE · 2019 to 2023
$1.9M
HDL and cardiovascular risk in chronic kidney diseaseR01HL111375 · NHLBI · UNIVERSITY OF WASHINGTON · PI HOOFNAGLE, ANDREW N · 2012 to 2015
$1.5M
Mentored research in the intersection of kidney and cardiovascular diseaseK26DK138333 · NIDDK · UNIVERSITY OF WASHINGTON · PI Nisha Bansal · 2023 to 2026
$440k
NHLBI NIH HHS R01 HL111375NIDDK NIH HHS K26 DK138333NIDDK NIH HHS P30 DK035816NIDDK NIH HHS R01 DK122075NIDDK NIH HHS R01 DK132155NIDDK NIH HHS T32 DK007467
6 · The paper itself

Abstract

backgroundPatients with chronic kidney disease (CKD) have dysfunctional high-density lipoprotein (HDL) particles as compared with the general population. Understanding the lipid composition of HDL may provide mechanistic insight. We tested associations of estimated glomerular filtration rate (eGFR) and albuminuria with relative HDL abundance of ceramides, sphingomyelins, and phosphatidylcholines in participants with CKD.

methodsWe studied 490 participants with CKD from the Seattle Kidney Study. HDL was isolated from plasma; targeted lipidomics was used to quantify the relative abundance of ceramides, sphingomyelins, and phosphatidylcholines per 10 µg of total HDL protein. We evaluated the associations of eGFR and albuminuria with levels of individual lipids and lipid classes (including 7 ceramides, 6 sphingomyelins, and 24 phosphatidylcholines) using multivariable linear regression, controlling for multiple comparisons via the false discovery rate.

resultsThe mean (SD) eGFR was 45 (24) mL/min/1.73 m2; the median (IQR[interquartile range]) albuminuria was 108 (16, 686) mg/g (12.2 [1.8, 77.6] mg/mmol) urine creatinine. After adjusting for demographics, past medical history, laboratory values, and medication use, eGFR was not associated with higher relative abundance of any class of lipids or individual lipids. Greater albuminuria was significantly associated with a higher relative abundance of total ceramides and moderate-long R-chain sphingomyelins, ceramides 22:0 and 24:1, hexosylceramide 16:0, sphingomyelin 16:0, and phosphatidylcholines 29:0, 30:1, and 38:2; the strongest association was for hexosylceramide 16:0 (increase per doubling of urine albumin to creatinine ratio 0.022 (95% CI, 0.012-0.032).

conclusionsGreater albuminuria was significantly associated with specific alterations in the lipid composition of HDL in participants with CKD.

Indexed as

AlbuminuriaRenal Insufficiency, ChronicCeramidesCreatinineGlomerular Filtration RateHumansLipidomicsLipoproteins, HDLPhosphatidylcholinesSphingomyelinsCeramidesCreatinineLipoproteins, HDLPhosphatidylcholinesSphingomyelins

Identifiers

PMID36644946
PMCPMC10069017

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.